Literature DB >> 33675538

Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.

Angelica Macauda1,2, Chiara Piredda2, Alyssa I Clay-Gilmour3, Juan Sainz4,5, Gabriele Buda6, Miroslaw Markiewicz7, Torben Barington8, Elad Ziv9, Michelle A T Hildebrandt10, Alem A Belachew10, Judit Varkonyi11, Witold Prejzner12, Agnieszka Druzd-Sitek13, John Spinelli14,15, Niels Frost Andersen16, Jonathan N Hofmann17, Marek Dudziński18, Joaquin Martinez-Lopez19, Elzbieta Iskierka-Jazdzewska20, Roger L Milne21,22,23, Grzegorz Mazur24, Graham G Giles21,22,23, Lene Hyldahl Ebbesen16, Marcin Rymko25, Krzysztof Jamroziak26, Edyta Subocz27, Rui Manuel Reis28,29, Ramon Garcia-Sanz30, Anna Suska31, Eva Kannik Haastrup32, Daria Zawirska33, Norbert Grzasko34,35, Annette Juul Vangsted32, Charles Dumontet36, Marcin Kruszewski37, Magdalena Dutka12, Nicola J Camp38, Rosalie G Waller38, Waldemar Tomczak39, Matteo Pelosini6, Małgorzata Raźny40, Herlander Marques29, Niels Abildgaard41, Marzena Wątek42, Artur Jurczyszyn31, Elizabeth E Brown43, Sonja Berndt17, Aleksandra Butrym24, Celine M Vachon44, Aaron D Norman44, Susan L Slager44, Federica Gemignani2, Federico Canzian1, Daniele Campa2.   

Abstract

Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype-tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10-7 either in EBV-transformed B-lymphocytes or whole blood. We genotyped the resulting 22 SNPs in 1327 MM cases from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and examined their association with overall survival (OS) and progression-free survival (PFS), adjusting for age, sex, country of origin and disease stage. Three polymorphisms in two genes (TBRG4-rs1992292, TBRG4-rs2287535 and ENTPD1-rs2153913) showed associations with OS at P < .05, with the former two also associated with PFS. The associations of two polymorphisms in TBRG4 with OS were replicated in 1277 MM cases from the International Lymphoma Epidemiology (InterLymph) Consortium. A meta-analysis of the data from IMMEnSE and InterLymph (2579 cases) showed that TBRG4-rs1992292 is associated with OS (hazard ratio = 1.14, 95% confidence interval 1.04-1.26, P = .007). In conclusion, we found biologically a plausible association between a SNP in TBRG4 and OS of MM patients.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.

Entities:  

Keywords:  eQTL; genetic polymorphisms; multiple myeloma; overall survival; progression-free survival

Mesh:

Substances:

Year:  2021        PMID: 33675538      PMCID: PMC8770990          DOI: 10.1002/ijc.33547

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  39 in total

1.  A genome-wide association study of global gene expression.

Authors:  Anna L Dixon; Liming Liang; Miriam F Moffatt; Wei Chen; Simon Heath; Kenny C C Wong; Jenny Taylor; Edward Burnett; Ivo Gut; Martin Farrall; G Mark Lathrop; Gonçalo R Abecasis; William O C Cookson
Journal:  Nat Genet       Date:  2007-09-16       Impact factor: 38.330

Review 2.  TGF-β-related mechanisms of bone destruction in multiple myeloma.

Authors:  Toshio Matsumoto; Masahiro Abe
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

3.  Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Authors:  María E Sarasquete; Joaquín Martínez-López; María C Chillón; Miguel Alcoceba; Luis A Corchete; Bruno Paiva; Noemi Puig; Elena Sebastián; Cristina Jiménez; Maria-Victoria Mateos; Albert Oriol; Laura Rosiñol; Luis Palomera; Ana I Teruel; Yolanda González; Juan J Lahuerta; Joan Bladé; Norma C Gutiérrez; Elena Fernández-Redondo; Marcos González; Jesús F San Miguel; Ramón García-Sanz
Journal:  Br J Haematol       Date:  2013-08-16       Impact factor: 6.998

4.  Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.

Authors:  Angelica Macauda; Eleonora Castelli; Gabriele Buda; Matteo Pelosini; Aleksandra Butrym; Marzena Watek; Marcin Kruszewski; Annette Juul Vangsted; Marcin Rymko; Krzysztof Jamroziak; Niels Abildgaard; Eva Kannik Haastrup; Grzegorz Mazur; Rafael Ríos; Artur Jurczyszyn; Daria Zawirska; Marek Dudziński; Małgorzata Raźny; Magdalena Dutka; Waldemar Tomczak; Anna Suska; Agnieszka Druzd-Sitek; Herlander Marques; Mario Petrini; Miroslaw Markiewicz; Joaquin Martinez-Lopez; Lene Hyldahl Ebbesen; Elżbieta Iskierka-Jażdżewska; Juan Sainz; Federico Canzian; Daniele Campa
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

5.  Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

Authors:  M Urashima; A Ogata; D Chauhan; M Hatziyanni; M B Vidriales; D A Dedera; R L Schlossman; K C Anderson
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

Review 6.  Multiple Myeloma: Diagnosis and Treatment.

Authors:  S Vincent Rajkumar; Shaji Kumar
Journal:  Mayo Clin Proc       Date:  2016-01       Impact factor: 7.616

7.  Current perspectives on the intensity of natural selection of MHC loci.

Authors:  Yoshiki Yasukochi; Yoko Satta
Journal:  Immunogenetics       Date:  2013-04-03       Impact factor: 2.846

8.  Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.

Authors:  Tobias Meißner; Anja Seckinger; Kari Hemminki; Uta Bertsch; Asta Foersti; Mathias Haenel; Jan Duering; Hans Salwender; Hartmut Goldschmidt; Gareth J Morgan; Dirk Hose; Niels Weinhold
Journal:  BMC Med Genomics       Date:  2015-12-30       Impact factor: 3.063

9.  A genome-wide study of Hardy-Weinberg equilibrium with next generation sequence data.

Authors:  Jan Graffelman; Deepti Jain; Bruce Weir
Journal:  Hum Genet       Date:  2017-04-03       Impact factor: 4.132

10.  The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Authors:  Carolina Terragna; Daniel Remondini; Marina Martello; Elena Zamagni; Lucia Pantani; Francesca Patriarca; Annalisa Pezzi; Giuseppe Levi; Massimo Offidani; Ilaria Proserpio; Giovanni De Sabbata; Paola Tacchetti; Clotilde Cangialosi; Fabrizio Ciambelli; Clara Virginia Viganò; Flores Angela Dico; Barbara Santacroce; Enrica Borsi; Annamaria Brioli; Giulia Marzocchi; Gastone Castellani; Giovanni Martinelli; Antonio Palumbo; Michele Cavo
Journal:  Oncotarget       Date:  2016-03-01
View more
  1 in total

1.  Personalized 3-Gene Panel for Prostate Cancer Target Therapy.

Authors:  Sanda Iacobas; Dumitru Andrei Iacobas
Journal:  Curr Issues Mol Biol       Date:  2022-01-15       Impact factor: 2.976

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.